cbdMD Inc (YCBD) — Titan Protect Analysis

YCBD

cbdMD Inc

Healthcare · ·

$0.72

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$8M

Total market value of the company

Trailing P/E

0.30

Very cheap relative to earnings

Forward P/E

-0.82

Based on estimated future earnings — lower means cheaper

Rev Growth

+18.8%

Year-over-year revenue change

Profit Margin

-13.3%

How much profit the company keeps from each dollar of revenue

ROE

-53.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$2.00

+176% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About cbdMD Inc

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as

https://www.cbdmd.com

Country: United States Employees: 42 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.020

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0217

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.685

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-62.5%

Historical annualised return based on price data

Max Drawdown

-91.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$2.56

72% below the year high

52W Low

$0.47

54% above the year low

Avg Volume

1,453,984

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$2.46

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

4.47

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

59.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-14.2%

Profit from core operations before interest and tax

Free Cash Flow

$-7,919,723

Negative — the business is spending more than it generates

Revenue (TTM)

$20M

Total revenue over the last 12 months

Net Income

$-3,110,127

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$2.00

Target Median

$2.00

Target Low

$2.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go